Two days after a C&EN feature summarized the amylin obesity class as cooled, Zealand Pharma and Roche announced ↗ on April 29 that they are formally advancing petrelintide ↗ into Phase 3 trials for chronic weight management, with initiation planned for the second half of 2026. The decision repositions petrelintide from "long-shot of the three" to "next non-GLP-1 obesity asset to actually run a registration program," behind only Novo's CagriSema in development sequence.
The Phase 2 readout that drove the decision is the part worth holding. ZUPREME-1 reported up to 10.7% weight loss with placebo-like tolerability. The first half of that number is in the same range as semaglutide ↗ pivotal data. The second half is the part that actually differentiates. Tirzepatide ↗ and semaglutide both produce significant gastrointestinal side effects that drive a meaningful percentage of patients off therapy in the first year. A weight-loss number that approaches GLP-1 efficacy without the GI tolerance penalty would be a different commercial proposition than what the news section called cooled two days ago, and the Phase 3 program is designed to test whether that profile holds at scale.
The Phase 3 design has two arms worth tracking. Petrelintide as monotherapy. And petrelintide in combination with enicepatide (CT-388), Roche's GLP-1 ↗ / GIP ↗ dual agonist. The combination arm is the more interesting test scientifically. If amylin layered on top of a GLP-1/GIP dual delivers more than either alone, the obesity drug class moves from incretin-only to incretin-plus-amylin. That was the broader question the C&EN piece flagged as undecided. Petrelintide-monotherapy data, plus the combination data, will be the answer.
Same-day context. Novo Nordisk previewed 52 abstracts for the European Congress on Obesity (ECO 2026) in May, including CagriSema REDEFINE 1 body composition data, cardiovascular risk analyses, and Wegovy ↗ variants. The Istanbul meeting in late May becomes the data showdown. CagriSema is the GLP-1-plus-amylin combination already running its own Phase 3 program; the ECO body-composition data will be the first major signal on whether the combination delivers the muscle-preservation profile that the amylin case was supposed to provide. Petrelintide's Phase 3 endorsement and CagriSema's body-composition readout, on the same week, frame the second half of 2026 as decision time for the entire amylin obesity class.
What the news section had wrong. The April 28 framing positioned petrelintide as the long-shot. The Phase 3 endorsement does not contradict that the broader class enthusiasm cooled, but it does mean petrelintide specifically is now in a different bucket. Roche does not run pivotal trials on programs they have lost confidence in, and they certainly do not partner monotherapy and combination arms simultaneously without a defensible read on both. The piece this corrects: the long-shot framing was premature for petrelintide. The class-status framing remains accurate, in that CagriSema versus tirzepatide head-to-head still decides the case at the broader level.
What this changes for the platform. The calcitonin-amylin receptor complex (CALCR/RAMP) ↗ target page on peptidemodel currently hosts pramlintide as the FDA-approved reference. The Phase 3 program, plus CagriSema's coming readout, will likely drive renewed interest in the amylin design space and a wave of longer-acting amylin analogs that researchers may want to model against the existing card.
The drug-development calendar implication is straightforward. Amylin obesity drugs were the GLP-1 successor story two years ago, then the cooled-bet story two days ago, and as of yesterday the back-on-track story. The data over the next twelve months will resolve which framing was right.